6533b823fe1ef96bd127e149

RESEARCH PRODUCT

New Insights into Potocki-Shaffer Syndrome: Report of Two Novel Cases and Literature Review

Geoffroy DelplancqEleonora Di GregorioGiovanni Battista FerreroAlfredo BruscoDiana CarliPaul KuentzSlavica TrajkovaLisa Pavinato

subject

LSD-CoRESTPotocki–Shaffer syndromeReviewBioinformaticsSCNAlcsh:RC321-57103 medical and health sciences0302 clinical medicineEpileptic encephalopathy; Infantile spasms; Intellectual disability; LSD-CoREST; PHF21A; Potocki-Shaffer; SCNA; West syndromePotocki-ShafferIntellectual disabilityMedicineCraniofaciallcsh:Neurosciences. Biological psychiatry. Neuropsychiatry030304 developmental biology0303 health sciencesbusiness.industryGeneral NeuroscienceWest Syndromewest syndromemedicine.diseasePhenotypePHF21Astomatognathic diseasesEpileptic spasmsepileptic encephalopathySCNAintellectual disability<i>PHF21A</i>businessHaploinsufficiency030217 neurology & neurosurgeryinfantile spasms

description

Potocki-Shaffer syndrome (PSS) is a rare non-recurrent contiguous gene deletion syndrome involving chromosome 11p11.2. Current literature implies a minimal region with haploinsufficiency of three genes, ALX4 (parietal foramina), EXT2 (multiple exostoses), and PHF21A (craniofacial anomalies, and intellectual disability). The rest of the PSS phenotype is still not associated with a specific gene. We report a systematic review of the literature and included two novel cases. Because deletions are highly variable in size, we defined three groups of patients considering the PSS-genes involved. We found 23 full PSS cases (ALX4, EXT2, and PHF21A), 14 cases with EXT2-ALX4, and three with PHF21A only. Among the latter, we describe a novel male child showing developmental delay, café-au-lait spots, liner postnatal overgrowth and West-like epileptic encephalopathy. We suggest PSS cases may have epileptic spasms early in life, and PHF21A is likely to be the causative gene. Given their subtle presentation these may be overlooked and if left untreated could lead to a severe type or deterioration in the developmental plateau. If our hypothesis is correct, a timely therapy may ameliorate PSS phenotype and improve patients’ outcomes. Our analysis also shows PHF21A is a candidate for the overgrowth phenotype.

https://doi.org/10.3390/brainsci10110788